Renée Buurman-Raaijmakers is a postdoctoral researcher at the Departments of Human Genetics and Medical Biosciences at Radboudumc. Her research focuses on the development of gene-editing (cell) therapies for myotonic dystrophy type 1 (DM1), a neuromuscular disorder caused by a pathogenic repeat expansion for which no curative treatment currently exists.

Since joining the field in 2017, she has steadily progressed from research assistant to PhD candidate, research fellow, and now postdoctoral researcher, while maintaining a continuous focus on the development of a gene-edited cell therapy for DM1.

Over the years, she has built extensive expertise in DM1 disease mechanisms, patient-derived cellular models, genome-editing approaches, advanced microscopy, and cell therapy development. Building on a strong track record in DM1 research, her current work is focused on translating promising gene-editing approaches toward future clinical application. Through close collaboration with experts from multiple disciplines, she aims to contribute to the development of safe and effective gene therapies that can ultimately improve the lives of individuals affected by DM1.

Beyond her research activities, Renée co-founded the Radboud Muscle Network at Radboudumc and served on the local organizing committee of the 14th International Myotonic Dystrophy Consortium Meeting (IDMC-14) in 2024.

LinkedIn: Renée Buurman-Raaijmakers | LinkedIn
ORCID: https://orcid.org/0000-0001-9495-4830

Thesis: Paving the road for a pericyte-based gene-modified therapy for myotonic dystrophy (10-04-2026)